Skip to main content
BC Innovations
Feature Story

Public-Private Partnership Roundup

Highlights of public-private partnerships from 1Q15

By Mark Zipkin, Staff Writer

PPP activity in 1Q15 picked up where it left off at the end of last year, with 54 new partnerships disclosed, and big pharmas or biotechs accounting for 20 of those collaborations. AstraZeneca plc led the way with six deals, including three announced on Jan. 29 involving the use of CRISPR technology in a research capacity. Boehringer Ingelheim GmbH announced three academic collaborations and Johnson & Johnson's Janssen Biotech Inc. subsidiary had two.

The way to Janssen is through the gut

Fishburn, C.S. "TBK1 and beyond." BioCentury Innovations (2015)
Martz, L. "CRISPR research for AZ." BioCentury Innovations (2015)

Read Article
  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial

Management Updates

There were no items published for this section in the most recent issue. Click more >> to read previously published items.